Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2000-06, Vol.2 (3), p.175-187
• Main Authors: Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., Group, The Sibutramine/Diabetes Clinical Study
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; antiobesity agents; Appetite Depressants - pharmacology; Appetite Depressants - therapeutic use; Blood Pressure - drug effects; Body Mass Index; Cyclobutanes - pharmacology; Cyclobutanes - therapeutic use; Diabetes Mellitus - drug therapy; Diabetes Mellitus, Type 2 - drug therapy; diet; Diet, Reducing; Double-Blind Method; Female; Humans; Hyperglycemia - prevention & control; Lipids; Male; Middle Aged; norepinephrine; Obesity; Quality of Life; serotonin; sibutramine; Treatment Outcome; Weight Loss - drug effects; Weight Loss - physiology
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1046/j.1463-1326.2000.00081.x

Summary Aim: To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent Methods: This study was a 24‐week, double‐blind, multicentre trial following a 5‐week placebo run‐in period. One hundred and seventy‐five obese (body mass index (b.m.i.) ≥27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53.5 years; mean weight 99.3 kg) or placebo (n = 86; mean age 55 years; mean weight 98.2 kg) at 16 participating centres. To achieve moderate calorie restriction (deficit ≥ 250–500 kcal/day), individual dietary counselling was accompanied by either placebo or sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, and maintained at 20 mg through week 24). The main outcome measures included changes in weight, b.m.i., waist and hip circumference, glycaemic control, lipid profile, and quality of life, and evaluation of reported adverse events. Results: Sixty‐seven per cent of sibutramine patients and 71% of placebo patients completed the study. At week 24 when comparing those who completed the course, sibutramine compared with placebo patients showed significantly greater (p